Sugi Predict

Sugi Predict / Compounds / SCHEMBL10067304

SCHEMBL10067304

SCHEMBL10067304

COc1ccc2c(c1)c(-c1nc3c4cccnc4c4ncccc4c3[nH]1)cn2C(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 4/20 0.51
▸ PDE4D Q08499 2/20 0.51
▸ MKNK1 Q9BUB5 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.44
▸ HTR2C P28335 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ HTR5A P47898 1/20 0.40
▸ HTR6 P50406 3/20 0.39
▸ PDE2A O00408 1/20 0.37
▸ AURKB Q96GD4 2/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ LCK P06239 1/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ GSK3A P49840 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ CDK7 P50613 1/20 0.37
▸ BTK Q06187 1/20 0.37
▸ LRRK2 Q5S007 1/20 0.37
▸ IDO1 P14902 1/20 0.36
▸ HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067279 0.86 CA12 (0.41) MKNK1MKNK2GSK3BCDK7IDO1
SCHEMBL28012500 0.78 GAA (0.54) PDE2AIDO1KDM4EMEN1ALDH1A1
SCHEMBL28013140 0.77 GAA (0.53) PDE2AIDO1KDM4EMEN1ALDH1A1
SCHEMBL5331780 0.76 AURKA (0.56) CDK1CCNB1AURKACCNB2CCNB3
SCHEMBL27196551 0.73 AURKA (0.58) JAK2AURKA
SCHEMBL10067329 0.73 EIF2AK2 (0.47) HTR6GSK3AGSK3BHTR7CDK1
SCHEMBL21180249 0.71 PDE5A (0.58) IDO1AURKAKDM4EMEN1ALDH1A1
SCHEMBL28295235 0.70 KDM4E (0.55) MKNK1MKNK2IDO1CDK1CDK2
SCHEMBL21180300 0.68 GAA (0.50) IDO1KDM4EMEN1ALDH1A1MAPT
SCHEMBL14579767 0.68 MAP4K4 (0.47) IDO1AURKAKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
WO-2010102393-A1 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS LORUS THERAPEUTICS INC. (CA) 2010-09-16 — — WO disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 PDE4B 4430/4885PDE4D 4548/4885MKNK1 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.